Status:
ACTIVE_NOT_RECRUITING
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)
Lead Sponsor:
Zhongda Hospital
Conditions:
Unresectable Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective, multicenter, real-world cohort study designed to evaluate the effectiveness and safety of atezolizumab plus bevacizumab (Atezo+Bev) combined with various locoregional therapie...
Detailed Description
Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide, with a particularly high burden in China and the Asia-Pacific region, where chronic hepatitis B virus (HBV) infection...
Eligibility Criteria
Inclusion
- Age ≥18 years at initiation of atezolizumab plus bevacizumab (Atezo+Bev)
- Histologically or radiologically confirmed unresectable hepatocellular carcinoma (uHCC) according to national guidelines
- Initiated first-line Atezo+Bev treatment between October 28, 2020 and July 31, 2025
- Received ≥1 locoregional therapy (TACE, HAIC, TARE, ablation, or radiotherapy) within ±2 months of Atezo+Bev initiation
- At least one follow-up record available after treatment initiation
Exclusion
- Prior systemic therapy for HCC before Atezo+Bev initiation
- Concurrent participation in interventional clinical trials at baseline
- Diagnosis of other malignancies at baseline (except basal cell carcinoma of the skin)
Key Trial Info
Start Date :
October 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
1136 Patients enrolled
Trial Details
Trial ID
NCT07204327
Start Date
October 28 2020
End Date
December 31 2026
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, China, 210009